XML 23 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   71,462,094        
Beginning balance at Dec. 31, 2021 $ 233,917 $ 7 $ 0 $ 497,128 $ (5,687) $ (257,531)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ (150,920)         (150,920)
Issuance of common stock to directors (in shares)   14,928        
Vesting of restricted stock units (in shares)   403,648        
Exercise of stock options (in shares) 937,217 937,217        
Exercise of stock options $ 25,432     25,432    
Stock-based compensation expense 38,830     38,830    
Other comprehensive loss (1,559)       (1,559)  
Ending balance (in shares) at Dec. 31, 2022   72,817,887        
Ending balance at Dec. 31, 2022 145,700 $ 7 0 561,390 (7,246) (408,451)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (111,441)         (111,441)
Issuance of common stock to directors (in shares)   19,687        
Vesting of restricted stock units (in shares)   430,582        
Vesting of restricted stock units $ (9,748)     (9,748)    
Exercise of stock options (in shares) 98,610 98,610        
Exercise of stock options $ 752     752    
Stock-based compensation expense 43,387     43,387    
Other comprehensive loss (16,309)       (16,309)  
Ending balance (in shares) at Dec. 31, 2023   73,366,766        
Ending balance at Dec. 31, 2023 52,341 $ 7 0 595,781 (23,555) (519,892)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (92,262)         (92,262)
Issuance of common stock to directors (in shares)   20,216        
Issuance of common stock to directors 0   369 (369)    
Vesting of restricted stock units (in shares)   418,899        
Vesting of restricted stock units $ (7,987)   5,546 (13,533)    
Exercise of stock options (in shares) 1,543,436 1,543,436        
Exercise of stock options $ 14,461   44,104 (29,643)    
Repurchase of common stock (in shares)   (1,320,531)        
Repurchase of common stock (50,019)   (50,019)      
Stock-based compensation expense 39,045     39,045    
Other comprehensive loss $ 11,781       11,781  
Ending balance (in shares) at Dec. 31, 2024 74,000,000.0 74,028,786        
Ending balance at Dec. 31, 2024 $ (32,640) $ 7 $ 0 $ 591,281 $ (11,774) $ (612,154)